Compare Eli Lilly And Co (LLY) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Ulta Beauty Inc — how do they compare? Eli Lilly And Co trades at $1,159.9 (market cap $1.02T), while Ulta Beauty Inc trades at $492.09 (market cap $20.98B). The key difference: Eli Lilly And Co is far larger — about 48.6× Ulta Beauty Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| LLY | ULTA | |
|---|---|---|
Market Cap | $1.02T | $20.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $706.82 |
52-Week Low | $625.65 | $450.75 |
Enterprise Value | $1.06T | $23.06B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
ULTA Beauty trades at $488.01, up 1.76% with a bullish technical signal despite mixed moving averages. The company maintains strong profitability with 39.33% gross margins and 47.45% ROE, though revenue growth has slowed to 0.9% in 2025. Recent leadership appointments and international expansion initiatives signal strategic positioning for future growth.
ULTA presents a compelling value opportunity with a 17.97 P/E ratio below historical averages, supported by 56.5% analyst buy ratings and a $618.29 consensus target. However, margin compression risks and competitive pressures require monitoring as the company navigates evolving consumer trends and expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
